[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut de Recerca Biomèdica de Lleida\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":99},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100623290","comprehensive-maintenance-program-a-health-haven-for-copd-in-lleidathe-napoleon-project-100623290",false,"NCT07394712","Comprehensive Maintenance Program: a Health Haven for COPD in Lleida.The NAPOLEON Project.","NAPOLEON","Inclusion Criteria:\n\n* Adults aged 40 to 75 years.\n* Confirmed medical diagnosis of chronic obstructive pulmonary disease (COPD) of moderate to severe severity, based on clinical evaluation and pulmonary function testing.\n* Clinically stable for at least 4 weeks following the last severe exacerbation, as confirmed by the treating pulmonologist.\n* Referred to an outpatient pulmonary rehabilitation program due to persistent symptoms and a history of exacerbations, with moderate to severe dyspnea (Medical Research Council \\[MRC\\] dyspnea scale score \\> 2), according to physician assessment.\n* Completed at least 6 out of 8 sessions of a standard 8-week initial pulmonary rehabilitation program.\n\nExclusion Criteria:\n\n* Presence of medical contraindications to physical exercise, including unstable cardiovascular conditions (e.g., recent myocardial infarction, uncontrolled arrhythmias), severe musculoskeletal or neurological disorders, recent surgery, or acute medical conditions (e.g., recent stroke) that impair participation.\n* Severe cognitive impairment that limits the ability to understand instructions or participate actively in the program.\n* Unstable psychiatric disorders that may compromise adherence to or continuity with the exercise regimen.\n* Lack of availability or refusal to attend the scheduled sessions of the community-based exercise program.\n* Participation in another pulmonary rehabilitation program within the 6 months prior to study enrollment.","ALL","40 Years","75 Years",{"count":20,"type":21},86,"ESTIMATED","INTERVENTIONAL",[24],"NA","Introduction:\n\nPulmonary rehabilitation programs (PRPs) are known to reduce symptoms such as dyspnea and fatigue, while improving functional capacity and quality of life in individuals with chronic obstructive pulmonary disease (COPD). However, the benefits of an initial pulmonary rehabilitation program (PRP) tend to diminish rapidly over time, prompting the development of strategies to maintain these effects. Such strategies include supervised exercise programs, telephone follow-ups, and home-based exercise regimens. Nevertheless, the optimal maintenance strategy remains uncertain.\n\nObjectives:\n\nThe primary objective is to evaluate the impact of a supervised, multidimensional maintenance PRP on symptoms and quality of life in individuals with COPD. Additionally, the study aims to compare exercise capacity, healthcare resource utilization, economic benefits, and participant perceptions between the intervention and control groups.\n\nMethodology:\n\nA 12-month randomized controlled trial (RCT) with two parallel groups will be conducted in adults with COPD who have completed an initial 8-week PRP. Participants will be randomly assigned in a 1:1 ratio to either the intervention or control group. The intervention group will undergo a maintenance PRP consisting of two weekly supervised exercise sessions and monthly educational sessions on COPD in a comprehensive health center over a 3-month period. The control group will receive standard clinical care recommendations regarding physical activity. Clinical evaluations will be conducted at four time points throughout the study: baseline (T0), 3 months (T1), 6 months (T2), and 12 months (T3). Full pulmonary function tests and anthropometric assessments will be performed at T0 and T3. Other variables, including symptom burden, quality of life, functional capacity, mental health, physical activity, sleep-wake pattern, and healthcare utilization, will be systematically collected at all four time points.",[27,28,29],"COPD - Chronic Obstructive Pulmonary Disease","Pulmonary Rehabilitation","Randomised Controlled Trial",[31,32,33],"Pulmonary rehabilitation","chronic obstructive pulmonary disease (COPD)","Randomised controlled trial","RECRUITING","2026-02-05",{"date":37,"type":38},"2026-02-06","ACTUAL",{"date":40,"type":38},"2025-10-01",{"date":42,"type":21},"2026-10",{"name":44,"class":45},"Institut de Recerca Biomèdica de Lleida","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100533467","genetic-susceptibility-to-predict-weight-loss-after-bariatric-surgery-100533467","NCT06226194","Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery","GENBASU","Inclusion Criteria:\n\n* Men and women between the ages of 18 and 65 at the time of surgery\n* SG or RYBP as bariatric procedure.\n* With a BMI≥35.0 kg\u002Fm2 with one or more comorbidities or a BMI\\>40.0 kg\u002Fm2 at the time of surgery.\n* Provision of an informed consent form signed and personally dated by the patient.\n* With available baseline data (anthropometric, analytical, surgical procedure, pharmacological therapies, and obesity-related comorbidities).\n\nExclusion Criteria:\n\n* Any previous gastrointestinal surgery\n* Treatment with any approved antiobesity drug in Spain (orlistat, liraglutide 3.0 mg and\u002For naltrexone\u002Fbupropion extended release) or systemic glucocorticoids for more than 4 consecutive weeks during the 3 years following BS\n* End stage kidney disease (eGFR \\\u003C15 ml\u002Fmin\u002F1.73m2) or liver cirrhosis at baseline\n* Patients who developed any major medical conditions that limits the practice of a healthy life within normal limits (advanced cardiovascular disease or heart failure, stroke with neurological sequelae, chronic pulmonary obstructive disease with dyspnea at minimal exertion, severe joint pathology, end stage renal failure, or active cancer)\n* Known type 1 diabetes or LADA diabetes\n* Women who become pregnant during the follow-up period\n* Current drug or alcohol abuse\n* Uncontrolled psychiatric illness or eating disorders developed during the follow-up period.","18 Years","65 Years",{"count":57,"type":21},6966,"3 Years","OBSERVATIONAL","Obesity is a complex chronic disease, in which both genetic and environmental factors are involved, that shows a great heterogeneity in the response to different weight loss programs. Identifying patients as responder or no responder to the different obesity treatment options is a concept of great interest, both due to the high prevalence of obesity and its high consumption of resources. More than 500,000 surgeries are performed every year around the world, of which approximately 30% will present unsatisfactory results.\n\nThe general objective is to carry out a multi-omics approach for the discovery and validation of markers of weight response to bariatric surgery (BS) in a large sample of people with severe obesity (n=6,966 men and women who underwent sleeve gastrectomy or gastric bypass, including an additional external validation set). Thus, the investigators want to know the integrated contribution of several genomic markers (Genome Wide Association study, GWAs), new clinical and analytical variables (human exposome concept) and gender perspective to the prediction of response to the intervention at 12 month and its long-term longitudinal maintenance (3 years). The investigators intend, therefore, to provide new evidence to advance towards precision medicine. The investigators will focus our attention also on identifying those patients who, after being classified at the weight loss nadir as responders experienced weight regain.",[62,63,64,65,66],"Bariatric Surgery Candidate","Obesity, Morbid","Genetic Predisposition","Metabolic Syndrome","Weight Loss","2024-03-05",{"date":69,"type":38},"2024-03-06",{"date":71,"type":21},"2024-03-15",{"date":73,"type":21},"2028-11-29",{"name":44,"class":45},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":84,"targetDuration":86,"studyType":59,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":5},"100522495","longitudinal-recovery-trajectories-after-an-acute-respiratory-distress-syndrome-a-new-understanding-100522495","NCT06083363","Longitudinal Recovery Trajectories After an Acute Respiratory Distress Syndrome, a New Understanding","Longitudinal Recovery Trajectories After an Acute Respiratory Distress Syndrome, a New Understanding. The TENACITY Study","TENACITY","Inclusion Criteria:\n\n* Male and female patients aged ≥18 years\n* Admission to the ICU\n* Diagnosis of severe pneumonia and\u002For diagnosis of acute respiratory distress syndrome (ARDS) based on the 2023 definition due to any origin (infectious and non-infectious)\n\nExclusion Criteria:\n\n* Life expectancy less than a year\n* Transfer to another hospital during hospitalization or follow-up\n* Stay in palliative care\n* Severe mental disability that makes it impossible to carry out pulmonary function tests during follow-up",{"count":85,"type":21},246,"12 Months","COVID-19 resulted in the largest cohort of critical illness survivors in history, heightened awareness of the importance of the respiratory sequelae after an acute distress respiratory syndrome (ADRS). Despite the advancement of acute-phase ARDS management, it is unknown whether there are differences in the longitudinal recovery trajectories between patients with post-ARDS due to COVID-19 and due to other causes. The main objective of the study is to identify risk factors of pulmonary sequela (lung diffusing capacity) at long-term follow-up in survivors of ARDS. The investigators are also interested in describing the long-term longitudinal recovery trajectories at a multi-dimensional level (symptoms, quality of life, neurocognitive, other lung function parameters, exercise capacity, chest imaging and molecular profiles) of ARDS survivors, and compared between ARDS caused by COVID-19. The ultimate goal is to understand the pathobiological mechanisms associated with a severe lung injury at the long term, allowing the introduction of clinical guidelines for the management of post-ARDS patients and the assignment of personalized interventions.",[89,90],"ARDS","ARDS Disease Progression",[89,92],"ICU",{"date":69,"type":38},{"date":95,"type":38},"2023-06-29",{"date":97,"type":21},"2026-12-31",{"name":44,"class":45},""]